National Bank of Canada FI Acquires 4,909 Shares of Sanofi (NASDAQ:SNY)

National Bank of Canada FI boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 1.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 338,899 shares of the company’s stock after purchasing an additional 4,909 shares during the period. National Bank of Canada FI’s holdings in Sanofi were worth $16,938,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. raised its stake in shares of Sanofi by 29.8% in the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after acquiring an additional 651,756 shares during the last quarter. Natixis Advisors L.P. grew its stake in Sanofi by 15.9% in the third quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after acquiring an additional 346,563 shares during the period. Morgan Stanley lifted its holdings in shares of Sanofi by 4.6% during the 3rd quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock valued at $392,796,000 after purchasing an additional 323,968 shares in the last quarter. Clough Capital Partners L P acquired a new position in shares of Sanofi in the 3rd quarter valued at approximately $14,719,000. Finally, Soros Fund Management LLC bought a new stake in Sanofi during the 3rd quarter worth approximately $11,533,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Morgan Stanley began coverage on Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Stock Up 0.5 %

Sanofi stock opened at $49.57 on Wednesday. The company has a fifty day simple moving average of $47.92 and a 200 day simple moving average of $48.14. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.72. The company has a market cap of $125.39 billion, a P/E ratio of 24.91, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is presently 69.35%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.